In today’s briefing:
- RoboTechnik H Share Listing (3757 HK): The Investment Case
- ESWIN Computing (奕斯伟计算) Pre-IPO: Tearsheet
- Tencent (700 HK): Synthetic Expert Call Transcript (24 Sep 2026)
- Kinwong Electronic H Share Listing (3228 HK): Valuation Insights
- Primer: Link REIT (823 HK) – Sep 2026
- The Ultimate Value Trap: Shorting Spring REIT Amid Beijing’s Office Supply Crisis
- CSPC Pharma (1093 HK): Finished Drugs, Licensing Up 1H26 Sales; SYS6010 Will Be Key In Near Future
- Dynamic Electronics (DYEL HK): Synthetic Expert Call Transcript (24 Sep 2026)
- Timeless: A Follow-Up on the Luxury Watch Retailer Space And Their Impressive Capital Allocation
- RoboTechnik IntelligentTechnology (RBTK2 HK): Synthetic Expert Call Transcript (24 Sep 2026)
RoboTechnik H Share Listing (3757 HK): The Investment Case
- RoboTechnik Intelligent Technology (RBTK HK) makes manufacturing equipment for the PV and silicon photonics (SiPh) industries. It is seeking to raise up to US$663 million at HK$436.00 per share.
- Its legacy PV business is collapsing, while SiPh assembly and testing equipment, acquired through ficonTEC in 2025, generated 80% of 1H26 revenue.
- The investment case is cautious: RoboTechnik leads a fast-growing SiPh niche, but is barely profitable, leveraged and goodwill-heavy, with a weak governance record.
ESWIN Computing (奕斯伟计算) Pre-IPO: Tearsheet
- ESWIN Computing, a RISC-V chip product provider, has passed the HKEX listing hearing and is seeking a Main Board listing. CITIC and CSC are the joint sponsors.
- We look at the company’s core segments: human-machine interaction and multimedia processing chip products, and interconnectivity and computing chip products.
- We then look at the company’s financial profile, loss-making status, pre-IPO valuation and investor backing.
Tencent (700 HK): Synthetic Expert Call Transcript (24 Sep 2026)
- Tencent’s massive AI pivot is reshaping its capital allocation strategy. The company’s Q2 2026 capital expenditure nearly tripled year-on-year to RMB 52.8 billion, driving reported free cash flow negative to negative RMB 13.8 billion. This has triggered a structural reduction in share buybacks, which are expected to drop to HKD 40 billion to HKD 60 billion in 2026, down from HKD 112 billion in 2024.
- WeChat Video Accounts (VA) remain the primary engine of near-term monetization, shields against ByteDance (Douyin), and the ultimate host for AI agents. VA user time spent grew over 20% year-on-year in Q2 2026, yet its ad-load remains low at 3% to 4% (compared to Douyin’s 10% to 12%), representing significant untapped pricing power and ad inventory headroom.
- Divestment of the listed investee portfolio (valued at RMB 673 billion as of late 2025) is transitioning from a regulatory defense mechanism to an active capital-funding tool. While domestic consumer tech holdings (like remaining stakes in Bilibili or KE Holdings) are prime monetization targets, Tencent is selectively redeploying capital toward international gaming M&A and high-performance computing clusters rather than returning all cash to shareholders.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Kinwong Electronic H Share Listing (3228 HK): Valuation Insights
- Shenzhen Kinwong Electronic (3228 HK) is a global printed circuit board (PCB) manufacturer, seeking to raise up to US$653 million at a maximum offer price of HK$69.88 per share.
- I discussed the H Share listing in Kinwong Electronic H Share Listing (3228 HK): The Investment Case.
- In this note, I present my forecasts and valuation. The AH discount is light compared to peer multiples. Given my concerns about fundamentals, I would avoid the listing.
Primer: Link REIT (823 HK) – Sep 2026
- Link REIT (823 HK) represents Asia’s largest and most defensively structured real estate investment trust, anchored by a HK$210B+ portfolio comprising necessity-focused neighbourhood retail, fresh wet markets, and car parks predominantly situated in Hong Kong’s high-density public housing estates.
- Despite headline statutory net losses in 2025 and 2026 driven entirely by non-cash property revaluation writedowns amid global cap rate expansions, underlying cash flows remain robust with operating cash flow of HK$6.82B in 2026 and an attractive forward distribution yield of ~6.80%.
- Management’s strategic pivot toward the ‘Link 3.0’ capital management framework—focused on capital recycling (e.g., partial divestment of 100 Market Street in Sydney), institutional joint ventures, and accretive unit buybacks—provides balance sheet resilience and supports long-term distribution per unit (DPU) stability.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
The Ultimate Value Trap: Shorting Spring REIT Amid Beijing’s Office Supply Crisis
- Yield Illusion: Spring REIT slashed its interim dividend as revenues plunged, trapping investors who expected a safe yield within a mathematically flawed, debt-heavy income vehicle.
- Supply Avalanche: A massive influx of Grade-A office supply in Beijing shifted pricing power entirely to tenants, triggering devastating negative rental reversions for the flagship asset.
- Leverage Vice: Shrinking property valuations and structurally elevated debt costs are driving the REIT perilously close to strict loan-to-value covenant breaches, accelerating fundamental destruction.
CSPC Pharma (1093 HK): Finished Drugs, Licensing Up 1H26 Sales; SYS6010 Will Be Key In Near Future
- CSPC Pharmaceutical (1093 HK) 1H26 revenue rose 40% YoY as finished drugs and licensing revenue, both witnessed growth. The company ended 1H26 with a net profit of RMB 6.5B.
- The finished drug segment achieved revenue of RMB 10.2B, up 11% YoY, with the nervous system and cardiovascular system revenue up 28% and 19% respectively.
- CSPC Pharmaceutical aims to expand into the high-end market to achieve competitive differentiation and thereby command higher prices. We remain bullish on the name.
Dynamic Electronics (DYEL HK): Synthetic Expert Call Transcript (24 Sep 2026)
- Volume Leadership vs. Price Squeeze: Dynamic Electronics is the undisputed global leader in automotive HDI PCBs, holding the No. 1 position by sales revenue. However, this volume leadership has come at the expense of profitability. Standard annual price-downs of 3% to 5% demanded by major Tier-1 automotive clients (Bosch, Continental, Valeo) are colliding with a severe upstream raw material cost squeeze.
- Upstream Supplier Power & Margin Squeeze: Upstream copper-clad laminate (CCL) and fiberglass cloth suppliers wield absolute pricing power. In 2026, aggressive price increases from giants like Kingboard (up to 20% on thin-cloth prepreg in August 2026) have compressed Dynamic’s parent-level gross margins to 14% as of Q2 2026 (a 2.1 percentage point contraction quarter-on-quarter).
- Capital Dilution & Thailand Execution Risks: Dynamic’s massive capital expenditure expansion—revised upward to NT$38.3 billion for 2026—is stretching the balance sheet during a period of net losses. The first phase of the Prachinburi, Thailand plant is facing operational learning curves and a delayed full-utilization target of Q1 2027. Coupled with a second Thai plant investment of CNY 3.3 billion and severe FX translation losses on the Thai Baht, Dynamic is suffering near-term net losses (reporting a net loss of NT$230 million in Q2 2026) despite a 33.3% YoY revenue jump in 1H 2026.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Timeless: A Follow-Up on the Luxury Watch Retailer Space And Their Impressive Capital Allocation
- This follows up on our piece, Ticking Different: A Comparison of the World’s Listed Luxury Watch Retailers With Exposure to Rolex, where we follow five listed luxury watch retailers.
- This is an update on the names as well as a valuation pit stop, heading into the earnings season for a few of the March-end companies
- We like Oriental Watch (398 HK) for its net cash position (~60% of market cap) and 12% dividend yield, and The Hour Glass (HG SP) for its buybacks and superior metrics.
RoboTechnik IntelligentTechnology (RBTK2 HK): Synthetic Expert Call Transcript (24 Sep 2026)
- Silicon Photonics (SiPh) Inflection Overcoming PV Cyclicality: RoboTechnik’s business model is undergoing a dramatic structural shift, with SiPh assembly and testing equipment—via the fully consolidated German subsidiary ficonTEC—rising to 80.3% of group revenue in 1H2026 (reaching RMB 488.2 million), successfully buffering the company against the massive capex downturn in the domestic photovoltaic (PV) market.
- Precision vs. Throughput Moat: While competitors like ASMPT (AMICRA) and Mycronic (MRSI) lead in high-throughput eutectic die-bonding (800+ UPH) with sub-micron capabilities, RoboTechnik’s ficonTEC dominates the hyper-precise, active optical multi-axis alignment space, achieving post-bond accuracies of <250 nm and rolling out pioneering double-sided electro-optical wafer-level test systems (WLT-D2) to drastically improve early-stage yield rates.
- IPO Capital Allocation and Profitability Headwinds: The pricing of RoboTechnik’s HK$4.9 billion (up to HK$5.18 billion) Hong Kong IPO on September 24, 2026, represents a crucial step to fund international manufacturing capacity and R&D. While group operations returned to a slim RMB 6.6 million net profit in 1H2026 (reversing an RMB 45.5 million net loss in FY2025), long-term margins depend on shifting ficonTEC from high-touch, customized engineering prototypes to standardized, scalable machines, alongside managing severe sole-source dependencies on Western motion-control suppliers.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.

